{"PubmedBookArticle": [], "PubmedArticle": [{"MedlineCitation": {"KeywordList": [["CBD", "Alcohol", "Alcohol Use Disorder", "Cannabidiol", "Pharmacotherapy"]], "SpaceFlightMission": [], "InvestigatorList": [], "OtherAbstract": [], "OtherID": [], "CitationSubset": ["IM"], "GeneralNote": [], "PMID": "30698831", "DateCompleted": {"Year": "2020", "Month": "07", "Day": "06"}, "DateRevised": {"Year": "2020", "Month": "07", "Day": "06"}, "Article": {"ArticleDate": [{"Year": "2019", "Month": "02", "Day": "19"}], "Language": ["eng"], "ELocationID": ["10.1111/acer.13964"], "Journal": {"ISSN": "1530-0277", "JournalIssue": {"Volume": "43", "Issue": "4", "PubDate": {"Year": "2019", "Month": "Apr"}}, "Title": "Alcoholism, clinical and experimental research", "ISOAbbreviation": "Alcohol Clin Exp Res"}, "ArticleTitle": "Cannabidiol as a Novel Candidate Alcohol Use Disorder Pharmacotherapy: A Systematic Review.", "Pagination": {"StartPage": "550", "EndPage": "563", "MedlinePgn": "550-563"}, "Abstract": {"AbstractText": ["There is substantial interest in the therapeutic potential of cannabidiol (CBD), a nonpsychoactive cannabinoid found in plants of the genus Cannabis. The goal of the current systematic review was to characterize the existing literature on this topic and to evaluate the credibility of CBD as a candidate pharmacotherapy for alcohol use disorder (AUD). Using a comprehensive search strategy, 303 unique potential articles were identified and 12 ultimately met criteria for inclusion (8 using rodent models, 3 using healthy adult volunteers, and 1 using cell culture). In both rodent and cell culture models, CBD was found to exert a neuroprotective effect against adverse alcohol consequences on the hippocampus. In rodent models, CBD was found to attenuate alcohol-induced hepatotoxicity, specifically, alcohol-induced steatosis. Finally, findings from preclinical rodent models also indicate that CBD attenuates cue-elicited and stress-elicited alcohol seeking, alcohol self-administration, withdrawal-induced convulsions, and impulsive discounting of delayed rewards. In human studies, CBD was well tolerated and did not interact with the subjective effects of alcohol. Collectively, given its favorable effects on alcohol-related harms and addiction phenotypes in preclinical models, CBD appears to have promise as a candidate AUD pharmacotherapy. This is further bolstered by the absence of abuse liability and its general tolerability. A clear limitation to the literature is the paucity of human investigations. Human preclinical and clinical studies are needed to determine whether these positive effects in model systems substantively translate into clinically relevant outcomes."], "CopyrightInformation": "\u00a9 2019 by the Research Society on Alcoholism."}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Michael G. DeGroote Centre for Medicinal Cannabis Research, McMaster University & St. Joseph's Healthcare Hamilton, Hamilton, Ontario, Canada."}, {"Identifier": [], "Affiliation": "Peter Boris Centre for Addictions Research, McMaster University & St. Joseph's Healthcare Hamilton, Hamilton, Ontario, Canada."}], "LastName": "Turna", "ForeName": "Jasmine", "Initials": "J"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Peter Boris Centre for Addictions Research, McMaster University & St. Joseph's Healthcare Hamilton, Hamilton, Ontario, Canada."}, {"Identifier": [], "Affiliation": "Department of Psychology, Neuroscience, and Behavior, McMaster University, Hamilton, Ontario, Canada."}, {"Identifier": [], "Affiliation": "Department of Psychiatry and Behavioural Neurosciences, McMaster University, Hamilton, Ontario, Canada."}], "LastName": "Syan", "ForeName": "Sabrina K", "Initials": "SK"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Psychiatry and Behavioural Neurosciences, McMaster University, Hamilton, Ontario, Canada."}, {"Identifier": [], "Affiliation": "Mood Disorders Program and Women's Health Concerns Clinic, St. Joseph's Healthcare Hamilton, Hamilton, Ontario, Canada."}], "LastName": "Frey", "ForeName": "Benicio N", "Initials": "BN"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Centre for Addiction and Mental Health, Toronto, Ontario, Canada."}, {"Identifier": [], "Affiliation": "Homewood Research Institute, Guelph, Ontario, Canada."}], "LastName": "Rush", "ForeName": "Brian", "Initials": "B"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Homewood Research Institute, Guelph, Ontario, Canada."}], "LastName": "Costello", "ForeName": "Mary Jean", "Initials": "MJ"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Addiction Medicine Service, Homewood Health Centre, Guelph, Ontario, Canada."}], "LastName": "Weiss", "ForeName": "Mark", "Initials": "M"}, {"Identifier": ["0000-0002-8695-1071"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Michael G. DeGroote Centre for Medicinal Cannabis Research, McMaster University & St. Joseph's Healthcare Hamilton, Hamilton, Ontario, Canada."}, {"Identifier": [], "Affiliation": "Peter Boris Centre for Addictions Research, McMaster University & St. Joseph's Healthcare Hamilton, Hamilton, Ontario, Canada."}, {"Identifier": [], "Affiliation": "Department of Psychology, Neuroscience, and Behavior, McMaster University, Hamilton, Ontario, Canada."}, {"Identifier": [], "Affiliation": "Department of Psychiatry and Behavioural Neurosciences, McMaster University, Hamilton, Ontario, Canada."}, {"Identifier": [], "Affiliation": "Homewood Research Institute, Guelph, Ontario, Canada."}], "LastName": "MacKillop", "ForeName": "James", "Initials": "J"}], "GrantList": [{"GrantID": "R01 AA025849", "Acronym": "AA", "Agency": "NIAAA NIH HHS", "Country": "United States"}, {"GrantID": "R01 AA025911", "Acronym": "AA", "Agency": "NIAAA NIH HHS", "Country": "United States"}, {"GrantID": "R01 AA024930", "Acronym": "AA", "Agency": "NIAAA NIH HHS", "Country": "United States"}], "PublicationTypeList": ["Journal Article", "Research Support, N.I.H., Extramural", "Systematic Review"]}, "MedlineJournalInfo": {"Country": "England", "MedlineTA": "Alcohol Clin Exp Res", "NlmUniqueID": "7707242", "ISSNLinking": "0145-6008"}, "ChemicalList": [{"RegistryNumber": "19GBJ60SN5", "NameOfSubstance": "Cannabidiol"}], "MeshHeadingList": [{"QualifierName": ["drug therapy"], "DescriptorName": "Alcoholism"}, {"QualifierName": [], "DescriptorName": "Animals"}, {"QualifierName": ["drug effects"], "DescriptorName": "Behavior, Animal"}, {"QualifierName": ["therapeutic use"], "DescriptorName": "Cannabidiol"}, {"QualifierName": [], "DescriptorName": "Humans"}], "CoiStatement": "Conflict of Interest. B.N.F has received research support from Pfizer and consultant fees from Otsuka. James MacKillop is a principal in BEAM Diagnostics, Inc. No other potential conflicts of interest to report."}, "PubmedData": {"ReferenceList": [{"ReferenceList": [], "Reference": [{"Citation": "American Psychiatric Association, 2013. Diagnostic and statistical manual of mental disorders (DSM-5\u00ae). American Psychiatric Pub."}, {"Citation": "Agurell S, Carlsson S, Lindgren JE, Ohlsson A, Gillespie H, Hollister L (1981) Assay of cannabinol and cannabidiol by mass fragmentography. Experientia 37: 1090\u20131092.", "ArticleIdList": ["6273208"]}, {"Citation": "Aizpurua-Olaizola O, Elezgarai I, Rico-Barrio I, Zarandona I, Etxebarria N, Usobiaga A (2017) Targeting the endocannabinoid system: future therapeutic strategies. Drug Discov Today 22: 105\u2013110.", "ArticleIdList": ["27554802"]}, {"Citation": "Amlung M, Vedelago L, Acker J, Balodis I, MacKillop J (2017) Steep delay discounting and addictive behavior: a meta\u2010analysis of continuous associations. Addiction 112: 51\u201362.", "ArticleIdList": ["PMC5148639", "27450931"]}, {"Citation": "Arias A, Feinn R, Oncken C, Covault J, Kranzler HR (2010) Placebo-controlled trial of zonisamide for the treatment of alcohol dependence. J Clin Psychopharmacol 30: 318\u2013322.", "ArticleIdList": ["PMC3157084", "20473070"]}, {"Citation": "Avraham Y, Grigoriadis NC, Poutahidis T, Vorobiev L, Magen I, Ilan Y, Mechoulam R, Berry EM (2011) Cannabidiol improves brain and liver function in a fulminant hepatic failure\u2010induced model of hepatic encephalopathy in mice. Brit J Pharmacol 162:1650\u20131658.", "ArticleIdList": ["PMC3057300", "21182490"]}, {"Citation": "Arnone M, Maruani J, Chaperon F, Thi\u00e9bot MH, Poncelet M, Soubri\u00e9 P, Le Fur G (1997) Selective inhibition of sucrose and ethanol intake by SR 141716, an antagonist of central cannabinoid (CB1) receptors. Psychopharmacol 132:104\u2013106.", "ArticleIdList": ["9272766"]}, {"Citation": "Aronson M, 2015. \nPsychosocial treatment of alcohol use disorder [UptoDate]\nhttps://www.uptodate.com/contents/psychosocial-treatment-of-alcohol-use-disorder.\nAccessed September 29, 2018."}, {"Citation": "Belgrave BE, Bird KD, Chesher GB, Jackson DM, Lubble KE, Starmer GA, Teo RKC (1979) The effect of cannabidiol, alone and in combination with ethanol, on human performance. Psychopharmacol 64:243\u2013246.", "ArticleIdList": ["115049"]}, {"Citation": "Bergamaschi M, Costa Queiroz R, Zuardi AW, Crippa AS (2011) Safety and side effects of cannabidiol, a Cannabis sativa constituent. Curr Drug Safety 6: 237\u2013249.", "ArticleIdList": ["22129319"]}, {"Citation": "Bird KD, Boleyn T, Chesher GB, Jackson DM, Starmer GA, Teo RKC (1980) Intercannabinoid and cannabinoid-ethanol interactions and their effects on human performance. Psychopharmacol 71:181\u2013188.", "ArticleIdList": ["6777818"]}, {"Citation": "Blodgett JC, Del Re AC, Maisel NC, Finney JW (2014) A meta\u2010analysis of topiramate\u2019s effects for individuals with alcohol use disorders. Alcohol Clin Exp Res 38:1481\u20131488.", "ArticleIdList": ["PMC4047180", "24796492"]}, {"Citation": "Boggs DL, Nguyen JD, Morgenson D, Taffe MA, Ranganathan M (2018) Clinical and Preclinical Evidence for Functional Interactions of Cannabidiol and \u0394 9-Tetrahydrocannabinol. Neuropsychopharmacol 43: 142\u2013154.", "ArticleIdList": ["PMC5719112", "28875990"]}, {"Citation": "Brady KT, Myrick H, Henderson S, Coffey SF (2002) The use of divalproex in alcohol relapse prevention: a pilot study. Drug Alcohol Depen 67:323\u2013330.", "ArticleIdList": ["12127203"]}, {"Citation": "Brenneman DE, Petkanas D, Kinney WA (2018) Pharmacological Comparisons Between Cannabidiol and KLS-13019. J Mol Neurosci 66:121\u2013134.", "ArticleIdList": ["PMC6150782", "30109468"]}, {"Citation": "Campos AC, Foga\u00e7a MV, Sonego AB, Guimaraes FS (2016) Cannabidiol, neuroprotection and neuropsychiatric disorders. Pharmacol Res 112:119\u2013127.", "ArticleIdList": ["26845349"]}, {"Citation": "Coelhoso CC, Engelke DS, Filev R, Silveira DX, Mello LE, Santos\u2010Junior JG, 2013. Temporal and behavioral variability in cannabinoid receptor expression in outbred mice submitted to ethanol\u2010induced locomotor sensitization paradigm. Alcohol Clin Exp Res 37:1516\u20131526.", "ArticleIdList": ["23647533"]}, {"Citation": "Colombo G, Agabio R, Fa M, Guano L, Loche A, Reali R, Gessa GL (1998) Reduction of voluntary ethanol intake in ethanol-preferring sP rats by the cannabinoid antagonist SR-141716. Alcohol Alcoholism 33:126\u201330.", "ArticleIdList": ["9566474"]}, {"Citation": "Colombo G, Serra S, Brunetti G, Gomez R, Melis S, Vacca G, Carai MA, Gessa G (2002) Stimulation of voluntary ethanol intake by cannabinoid receptor agonists in ethanol-preferring sP rats. Psychopharmacol 159:181\u2013187.", "ArticleIdList": ["11862347"]}, {"Citation": "Consroe P, Carlini EA, Zwicker AP, Lacerda LA (1979) Interaction of cannabidiol and alcohol in humans. Psychopharmacol 66: 45\u201350.", "ArticleIdList": ["120541"]}, {"Citation": "Crews FT, Boettiger CA (2009) Impulsivity, frontal lobes and risk for addiction. Pharmacol Biochem Beh 93: 237\u2013247.", "ArticleIdList": ["PMC2730661", "19410598"]}, {"Citation": "Crews FT, Nixon K (2008) Mechanisms of neurodegeneration and regeneration in alcoholism. Alcohol Alcoholism 44:115\u2013127.", "ArticleIdList": ["PMC2948812", "18940959"]}, {"Citation": "Cunha JM, Carlini EA, Pereira AE, Ramos OL, Pimentel C, Gagliardi R, Sanvito WL, Lander N, Mechoulam R (1980) Chronic administration of cannabidiol to healthy volunteers and epileptic patients. Pharmacology 21:175\u2013185.", "ArticleIdList": ["7413719"]}, {"Citation": "Devinsky O, Cross JH, Laux L, Marsh E, Miller I, Nabbout R, Scheffer IE, Thiele EA, Wright S (2017) Trial of cannabidiol for drug-resistant seizures in the Dravet syndrome. NEJM 376: 2011\u20132020.", "ArticleIdList": ["28538134"]}, {"Citation": "Devinsky O, Patel AD, Cross JH, Villanueva V, Wirrell EC, Privitera M, Greenwood SM, Roberts C, Checketts D, VanLandingham KE, Zuberi SM (2018a) Effect of Cannabidiol on Drop Seizures in the Lennox\u2013Gastaut Syndrome. NEJM 378:1888\u20131897.", "ArticleIdList": ["29768152"]}, {"Citation": "Devinsky O, Patel AD, Thiele EA, Wong MH, Appleton R, Harden CL, Greenwood S, Morrison G, Sommerville K, GWPCARE1 Part A Study Group (2018b) Randomized, dose-ranging safety trial of cannabidiol in Dravet syndrome. Neurology 2018: e1\u2013e8.", "ArticleIdList": ["PMC5890607", "29540584"]}, {"Citation": "Englund A, Atakan Z, Kralj A, Tunstall N, Murray R, Morrison P (2016) The effect of five day dosing with THCV on THC-induced cognitive, psychological and physiological effects in healthy male human volunteers: a placebo-controlled, double-blind, crossover pilot trial. J Psychopharmacol 30:140\u2013151.", "ArticleIdList": ["26577065"]}, {"Citation": "FDA, 2018. \nEpidiolex \u2013 Precribing information\nJune 2018.\nAvailable at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210365lbl.pdf.\nAccessed on November 11, 2018."}, {"Citation": "Femen\u00eda T, Garc\u00eda\u2010Guti\u00e9rrez MS, Manzanares J (2010) CB1 receptor blockade decreases ethanol intake and associated neurochemical changes in fawn\u2010hooded rats. Alcohol Clin Exp Res 34:131\u2013141.", "ArticleIdList": ["19860799"]}, {"Citation": "Fertig JB, Ryan ML, Falk DE, Litten RZ, Mattson ME, Ransom J, Rickman WJ, Scott C, Ciraulo D, Green AI, Tiouririne NA (2012) A double\u2010blind, placebo\u2010controlled trial assessing the efficacy of levetiracetam extended\u2010release in very heavy drinking alcohol\u2010dependent patients. Alcohol Clin Exp Res 36:1421\u20131430.", "ArticleIdList": ["PMC3355217", "22324516"]}, {"Citation": "Filev R, Engelke DS, Da Silveira DX, Mello LE, Santos-Junior JG (2017) THC inhibits the expression of ethanol-induced locomotor sensitization in mice. Alcohol 65: 31\u201335.", "ArticleIdList": ["29084627"]}, {"Citation": "Fouad AA, Al-Mulhim AS, Gomaa W (2013) Protective effect of cannabidiol against cadmium hepatotoxicity in rats. J Trace Elem Med Bio 27:355\u2013363.", "ArticleIdList": ["23993482"]}, {"Citation": "Gomer B, Wagner K, Frings L, Saar J, Carius A, H\u00e4rle M, Steinhoff BJ, Schulze-Bonhage A (2007) The influence of antiepileptic drugs on cognition: a comparison of levetiracetam with topiramate. Epilepsy Behav 10:486\u2013494.", "ArticleIdList": ["17409025"]}, {"Citation": "Gonzalez-Cuevas G, Martin-Fardon R, Kerr TM, Stouffer DG, Parsons LH, Hammell DC, Banks SL, Stinchcomb AL, Weiss F (2018) Unique treatment potential of cannabidiol for the prevention of relapse to drug use: preclinical proof of principle. Neuropsychopharmacol, 43:2036\u20132045.", "ArticleIdList": ["PMC6098033", "29686308"]}, {"Citation": "Hamelink C, Hampson A, Wink DA, Eiden LE, Eskay RL (2005) Comparison of cannabidiol, antioxidants, and diuretics in reversing binge ethanol-induced neurotoxicity. J Pharmacol Exp Ther 314:780\u2013788.", "ArticleIdList": ["PMC4183207", "15878999"]}, {"Citation": "Hampson AJ, Grimaldi M, Axelrod J, Wink D (1998) Cannabidiol and (\u2212) \u03949-tetrahydrocannabinol are neuroprotective antioxidants. PNAS 95: 8268\u20138273.", "ArticleIdList": ["PMC20965", "9653176"]}, {"Citation": "Health Canada. Fact Sheet \u2013 Sativex [Health Canada website]\nAugust 1, 2007. \nAvailable at: https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/notice-compliance/conditions/fact-sheet-sativex-tetranabinex-nabidiolex.html . Accessed November 10, 2018."}, {"Citation": "Hern\u00e1ndez JA, L\u00f3pez-S\u00e1nchez RC, Rend\u00f3n-Ram\u00edrez A (2016) Lipids and oxidative stress associated with ethanol-induced neurological damage. Oxid Med Cell Longev 2016:1\u201315.", "ArticleIdList": ["PMC4753689", "26949445"]}, {"Citation": "Jastrz\u0119bska I, Zwolak A, Szczyrek M, Wawryniuk A, Skrzyd\u0142o-Radoma\u0144ska B, Daniluk J (2016) Biomarkers of alcohol misuse: recent advances and future prospects. Prz Gastroenterol 11:78\u201389.", "ArticleIdList": ["PMC4916243", "27350834"]}, {"Citation": "Jesse S, Br\u00e5then G, Ferrara M, Keindl M, Ben\u2010Menachem E, Tanasescu R, Brodtkorb E, Hillbom M, Leone MA, Ludolph AC (2017) Alcohol withdrawal syndrome: mechanisms, manifestations, and management. Acta Neurol Scand 135: 4\u201316.", "ArticleIdList": ["PMC6084325", "27586815"]}, {"Citation": "Johnson BA, Ait-Daoud N, Bowden CL, DiClemente CC, Roache JD, Lawson K, Javors MA, Ma JZ (2003) Oral topiramate for treatment of alcohol dependence: a randomised controlled trial. Lancet 361:1677\u20131685.", "ArticleIdList": ["12767733"]}, {"Citation": "Johnson BA, Rosenthal N, Capece JA, Wiegand F, Mao L, Beyers K, McKay A, Ait-Daoud N, Anton RF, Ciraulo DA, Kranzler HR (2007) Topiramate for treating alcohol dependence: a randomized controlled trial. JAMA 298:1641\u20131651.", "ArticleIdList": ["17925516"]}, {"Citation": "Jonas DE, Amick HR, Feltner C, Bobashev G, Thomas K, Wines R, Kim MM, Shanahan E, Gass CE, Rowe CJ, Garbutt JC (2014) Pharmacotherapy for adults with alcohol use disorders in outpatient settings: a systematic review and meta-analysis. JAMA 311: 1889\u20131900.", "ArticleIdList": ["24825644"]}, {"Citation": "Justinova Z, Munzar P, Panlilio LV, Yasar S, Redhi GH, Tanda G, Goldberg SR (2008) Blockade of THC-seeking behavior and relapse in monkeys by the cannabinoid CB 1-receptor antagonist rimonabant. Neuropsychopharmacol 33: 2870\u20132877.", "ArticleIdList": ["PMC2585511", "18305459"]}, {"Citation": "Kathmann M, Flau K, Redmer A, Tr\u00e4nkle C, Schlicker E (2006) Cannabidiol is an allosteric modulator at mu-and delta-opioid receptors. Naunyn Schmiedebergs Arch Pharmacology 372: 354\u2013361.", "ArticleIdList": ["16489449"]}, {"Citation": "Klumpers LE, Fridberg M, de Kam ML, Little PB, Jensen NO, Kleinloog HD, Elling CE, van Gerven JM (2013) Peripheral selectivity of the novel cannabinoid receptor antagonist TM38837 in healthy subjects. Brit J Clin Pharmacol 76: 846\u2013857.", "ArticleIdList": ["PMC3845308", "23601084"]}, {"Citation": "Knapp CM, Ciraulo DA, Sarid-Segal O, Richardson MA, Devine E, Streeter CC, Oscar-Berman M, Surprise C, Colaneri L, Putnam M, Waters M (2015) Zonisamide, topiramate, and levetiracetam: efficacy and neuropsychological effects in alcohol use disorders. J Clin Psychopharmacol 35: 34\u201342.", "ArticleIdList": ["PMC4276485", "25427171"]}, {"Citation": "Knapp CM, Mercado M, Markley TL, Crosby S, Ciraulo DA, Kornetsky C (2007) Zonisamide decreases ethanol intake in rats and mice. Pharmacol Biochem Beh 87(1), pp.65\u201372.", "ArticleIdList": ["PMC2867456", "17482246"]}, {"Citation": "Knapp CM, Sarid-Segal O, Richardson MA, Colaneri LS, Afshar M, Devine E, Streeter CC, Piechniczek-Buczek J, Ciraulo DA (2010) Open label trial of the tolerability and efficacy of zonisamide in the treatment of alcohol dependence. Am J Drug Alcohol Ab 36:102\u2013105.", "ArticleIdList": ["PMC4667705", "20337506"]}, {"Citation": "Kranzler HR, Soyka M (2018) Diagnosis and pharmacotherapy of alcohol use disorder: a review. JAMA 320: 815\u2013824.", "ArticleIdList": ["PMC7391072", "30167705"]}, {"Citation": "Laprairie RB, Bagher AM, Kelly MEM, Denovan\u2010Wright EM (2015) Cannabidiol is a negative allosteric modulator of the cannabinoid CB1 receptor. Brit J Pharmacol 172: 4790\u20134805.", "ArticleIdList": ["PMC4621983", "26218440"]}, {"Citation": "Leggio L, Lee MR (2017) Treatment of alcohol use disorder in patients with alcoholic liver disease. The Am J Med 130:124\u2013134.", "ArticleIdList": ["PMC5263063", "27984008"]}, {"Citation": "Leung JG, Hall-Flavin D, Nelson S, Schmidt KA, Schak KM (2015) The role of gabapentin in the management of alcohol withdrawal and dependence. Ann Pharmacother 49:897\u2013906.", "ArticleIdList": ["25969570"]}, {"Citation": "Li S, Tan HY, Wang N, Zhang ZJ, Lao L, Wong CW, Feng Y (2015) The role of oxidative stress and antioxidants in liver diseases. Int J Mol Sci 16: 26087\u201326124.", "ArticleIdList": ["PMC4661801", "26540040"]}, {"Citation": "Liput DJ, Hammell DC, Stinchcomb AL, Nixon K (2013) Transdermal delivery of cannabidiol attenuates binge alcohol-induced neurodegeneration in a rodent model of an alcohol use disorder. Pharmacol Biochem Be 111:120\u2013127.", "ArticleIdList": ["PMC4096899", "24012796"]}, {"Citation": "Litten RZ, Egli M, Heilig M, Cui C, Fertig JB, Ryan ML, Falk DE, Moss H, Huebner R, Noronha A (2012) Medications development to treat alcohol dependence: a vision for the next decade. Addict Biol 17: 513\u2013527.", "ArticleIdList": ["PMC3484365", "22458728"]}, {"Citation": "Litten RZ, Wilford BB, Falk DE, Ryan ML, Fertig JB (2016) Potential medications for the treatment of alcohol use disorder: an evaluation of clinical efficacy and safety. Subst Abus 37:286\u2013298.", "ArticleIdList": ["26928397"]}, {"Citation": "Litten RZ, Falk DE, Ryan ML, Fertig JB (2016) Discovery, development, and adoption of medications to treat alcohol use disorder: Goals for the phases of medications development. Alcohol Clin Exp Res 40:1368\u20131379.", "ArticleIdList": ["PMC4930402", "27184259"]}, {"Citation": "MacKillop J, Amlung MT, Few LR, Ray LA, Sweet LH, Munaf\u00f2 MR (2011) Delayed reward discounting and addictive behavior: a meta-analysis. Psychopharmacol 216: 305\u2013321.", "ArticleIdList": ["PMC3201846", "21373791"]}, {"Citation": "MacKillop J, Kahler CW (2009) Delayed reward discounting predicts treatment response for heavy drinkers receiving smoking cessation treatment. Drug Alcohol Depend 104:197\u2013203.", "ArticleIdList": ["PMC2740648", "19570621"]}, {"Citation": "MacKillop J, Miranda JR, Monti PM, Ray LA, Murphy JG, Rohsenow DJ, McGeary JE, Swift RM, Tidey JW, Gwaltney CJ (2010) Alcohol demand, delayed reward discounting, and craving in relation to drinking and alcohol use disorders. J Abnorm Psychol 119: 106\u2013114.", "ArticleIdList": ["PMC2862264", "20141247"]}, {"Citation": "Majchrowicz E (1975) Induction of physical dependence upon ethanol and the associated behavioral changes in rats. Psychopharmacologia 43:245\u2013254.", "ArticleIdList": ["1237914"]}, {"Citation": "Mechoulam R, Peters M, Murillo\u2010Rodriguez E, Hanu\u0161 LO (2007) Cannabidiol\u2013recent advances. Chem Biodivers 4: 1678\u20131692.", "ArticleIdList": ["17712814"]}, {"Citation": "Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(7): e1000097. doi:10.1371/journal.pmed1000097", "ArticleIdList": ["10.1371/journal.pmed1000097", "PMC2707599", "19621072"]}, {"Citation": "Navarrete F, Rubio G, Manzanares J (2014). Effects of naltrexone plus topiramate on ethanol self\u2010administration and tyrosine hydroxylase gene expression changes. Addict Biol 19:862\u2013873.", "ArticleIdList": ["23573810"]}, {"Citation": "Neupane SP (2016) Neuroimmune interface in the comorbidity between alcohol use disorder and major depression. Front Immunol 7:655\u2013666.", "ArticleIdList": ["PMC5186784", "28082989"]}, {"Citation": "Oberlin BG, Grahame NJ (2009) High\u2010alcohol preferring mice are more impulsive than low\u2010alcohol preferring mice as measured in the delay discounting task. Alcohol Clin Exp Res 33:1294\u20131303.", "ArticleIdList": ["PMC2872785", "19389183"]}, {"Citation": "Paille F & Martini H (2014) Nalmefene: a new approach to the treatment of alcohol dependence. Sub Abus Rehab 5: 87\u201394.", "ArticleIdList": ["PMC4133028", "25187751"]}, {"Citation": "Palpacuer C, Duprez R, Huneau A, Locher C, Boussageon R, Laviolle B, Naudet F (2018) Pharmacologically controlled drinking in the treatment of alcohol dependence or alcohol use disorders: a systematic review with direct and network meta\u2010analyses on nalmefene, naltrexone, acamprosate, baclofen and topiramate. Addiction 113:220\u2013237.", "ArticleIdList": ["28940866"]}, {"Citation": "Parker LA, Mechoulam R, Schlievert C (2002) Cannabidiol, a non-psychoactive component of cannabis and its synthetic dimethylheptyl homolog suppress nausea in an experimental model with rats. Neuroreport 13: 567\u2013570.", "ArticleIdList": ["11973447"]}, {"Citation": "Prud\u2019homme M, Cata R, Jutras-Aswad D (2015) Cannabidiol as an intervention for addictive behaviors: a systematic review of the evidence. Subst abus 9:33\u201338", "ArticleIdList": ["PMC4444130", "26056464"]}, {"Citation": "Ramo DE, Brown SA (2008) Classes of substance abuse relapse situations: a comparison of adolescents and adults. Psychol Addict Behav 22: 372\u2013379.", "ArticleIdList": ["PMC3031179", "18778130"]}, {"Citation": "Rando K, Hong KI, Bhagwagar Z, Li CSR, Bergquist K, Guarnaccia J, Sinha R (2011) Association of frontal and posterior cortical gray matter volume with time to alcohol relapse: a prospective study. Am J Psychiatry 168:183\u2013192.", "ArticleIdList": ["PMC3668974", "21078704"]}, {"Citation": "Richter C, Effenberger S, Bschor T, Bonnet U, Haasen C, Preuss UW, Heinz A, F\u00f6rg A, Volkmar K, Glauner T, Schaefer M (2012) Efficacy and safety of levetiracetam for the prevention of alcohol relapse in recently detoxified alcohol-dependent patients: a randomized trial. J Clin Psychopharmacol 32: 558\u2013562.", "ArticleIdList": ["22722516"]}, {"Citation": "Rubio G, L\u00f3pez-Mu\u00f1oz F, Ferre F, Mart\u00ednez-Gras I, Ponce G, Pascual JM, Jim\u00e9nez-Arriero MA, Alamo C (2010) Effects of zonisamide in the treatment of alcohol dependence. Clin Neuropharmacol 33:250\u2013253.", "ArticleIdList": ["20811276"]}, {"Citation": "Russo EB, Burnett A, Hall B, Parker KK (2005) Agonistic properties of cannabidiol at 5-HT1a receptors. Neurochem Res 30: 1037\u20131043.", "ArticleIdList": ["16258853"]}, {"Citation": "Ryberg E, Larsson N, Sj\u00f6gren S, Hjorth S, Hermansson NO, Leonova J, Elebring T, Nilsson K, Drmota T, Greasley PJ (2007) The orphan receptor GPR55 is a novel cannabinoid receptor. Brit J Pharmacol 152: 1092\u20131101.", "ArticleIdList": ["PMC2095107", "17876302"]}, {"Citation": "Sarid-Segal O, Knapp CM, Burch W, Richardson MA, Bahtia S, DeQuattro K, Afshar M, Richambault C, Sickels L, Devine E, Ciraulo DA (2009) The anticonvulsant zonisamide reduces ethanol self-administration by risky drinkers. Am J Drug Alcohol Ab 35:316\u2013319.", "ArticleIdList": ["PMC4028067", "19637104"]}, {"Citation": "Sinha R (2012) How does stress lead to risk of alcohol relapse? Alcohol Res-Curr Rev 34:432\u2013440.", "ArticleIdList": ["PMC3788822", "23584109"]}, {"Citation": "Sheffer C, MacKillop J, McGeary J, Landes R, Carter L, Yi R, Jones B, Christensen D, Stitzer M, Jackson L, Bickel W (2012) Delay discounting, locus of control, and cognitive impulsiveness independently predict tobacco dependence treatment outcomes in a highly dependent, lower socioeconomic group of smokers. Am J Addiction 21:221\u2013232.", "ArticleIdList": ["PMC3567840", "22494224"]}, {"Citation": "Stevens L, Goudriaan AE, Verdejo-Garcia A, Dom G, Roeyers H, Vanderplasschen W (2015) Impulsive choice predicts short-term relapse in substance-dependent individuals attending an in-patient detoxification programme. Psychol Med 45: 2083\u20132093.", "ArticleIdList": ["25640022"]}, {"Citation": "Swift R (2007) Emerging approaches to managing alcohol dependence. Am J Health-Syst Ph 64:S12\u2013S22.", "ArticleIdList": ["17322178"]}, {"Citation": "Thiele EA, Marsh ED, French JA, Mazurkiewicz-Beldzinska M, Benbadis SR, Joshi C, Lyons PD, Taylor A, Roberts C, Sommerville K, Gunning B (2018) Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 391: 1085\u20131096.", "ArticleIdList": ["29395273"]}, {"Citation": "Tucker JA, Foushee HR, Black BC (2008) Behavioral economic analysis of natural resolution of drinking problems using IVR self-monitoring. Exp Clin Psychopharm 16:332\u2013340.", "ArticleIdList": ["PMC2585360", "18729688"]}, {"Citation": "Tucker JA, Vuchinich RE, Rippens PD (2002) Predicting natural resolution of alcohol-related problems: A prospective behavioral economic analysis. Exp Clin Psychopharm 10: 248\u2013257.", "ArticleIdList": ["12233985"]}, {"Citation": "Vanderschuren LJ, Pierce RC (2010) Sensitization processes in drug addiction. Curr Top Behav Neurosci 3:179\u2013195", "ArticleIdList": ["21161753"]}, {"Citation": "Vilela LR, Gomides LF, David BA, Antunes MM, Diniz AB, Moreira FDA, Menezes GB (2015) Cannabidiol rescues acute hepatic toxicity and seizure induced by cocaine. Mediat Inflamm 2015:1\u201312.", "ArticleIdList": ["PMC4427116", "25999668"]}, {"Citation": "Viudez-Mart\u00ednez A, Garc\u00eda-Guti\u00e9rrez MS, Navarr\u00f3n CM, Morales-Calero MI, Navarrete F, Torres-Su\u00e1rez AI, Manzanares J (2018a) Cannabidiol reduces ethanol consumption, motivation and relapse in mice. Addict Biol 23:154\u2013164.", "ArticleIdList": ["28194850"]}, {"Citation": "Viudez-Mart\u00ednez A, Garc\u00eda\u2010Guti\u00e9rrez MS, Fraguas\u2010S\u00e1nchez AI, Torres\u2010Su\u00e1rez AI, Manzanares J (2018b) Effects of cannabidiol plus naltrexone on motivation and ethanol consumption. Brit J Pharmacol 175:3369\u20133378.", "ArticleIdList": ["PMC6057893", "29859012"]}, {"Citation": "Wang L, Liu J, Harvey-White J, Zimmer A, Kunos G (2003) Endocannabinoid signaling via cannabinoid receptor 1 is involved in ethanol preference and its age-dependent decline in mice. PNAS 100: 1393\u20131398.", "ArticleIdList": ["PMC298783", "12538878"]}, {"Citation": "Wang Y, Mukhopadhyay P, Cao Z, Wang H, Feng D, Hask\u00f3 G, Mechoulam R, Gao B, Pacher P (2017) Cannabidiol attenuates alcohol-induced liver steatosis, metabolic dysregulation, inflammation and neutrophil-mediated injury. Sci Rep 7:1\u201312.", "ArticleIdList": ["PMC5608708", "28935932"]}, {"Citation": "Wilhelm CJ, Mitchell SH (2009) Strain differences in delay discounting using inbred rats. Genes Brain Behav 8:426\u2013434.", "ArticleIdList": ["PMC2825220", "19243451"]}, {"Citation": "Wilson S, Bair JL, Thomas KM, Iacono WG (2017) Problematic alcohol use and reduced hippocampal volume: a meta-analytic review. Psychol Med 47:2288\u20132301.", "ArticleIdList": ["PMC5595646", "28374654"]}, {"Citation": "Yang L, Rozenfeld R, Wu D, Devi LA, Zhang Z, Cederbaum A (2014) Cannabidiol protects liver from binge alcohol-induced steatosis by mechanisms including inhibition of oxidative stress and increase in autophagy. Free Radical Bio Med 68: 260\u2013267.", "ArticleIdList": ["PMC4112960", "24398069"]}, {"Citation": "Zuardi AW, Crippa JAS, Hallak JEC, Moreira FA, Guimaraes FS (2006) Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug. Braz J Med Biol Res 39: 421\u2013429.", "ArticleIdList": ["16612464"]}]}], "History": [{"Year": "2018", "Month": "12", "Day": "22"}, {"Year": "2019", "Month": "1", "Day": "20"}, {"Year": "2019", "Month": "1", "Day": "31", "Hour": "6", "Minute": "0"}, {"Year": "2020", "Month": "7", "Day": "7", "Hour": "6", "Minute": "0"}, {"Year": "2019", "Month": "1", "Day": "31", "Hour": "6", "Minute": "0"}, {"Year": "2020", "Month": "4", "Day": "1"}], "PublicationStatus": "ppublish", "ArticleIdList": ["30698831", "NIHMS1008447", "PMC6910215", "10.1111/acer.13964"]}}]}